On this page

Ciprofloxacin Hydrochloride

Prescription NDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Ciprofloxacin Hydrochloride
Generic name
Ciprofloxacin Hydrochloride
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
NDA AUTHORIZED GENERIC · NDA AG
Labeler
NuCare Pharmaceuticals,Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
11
Packages
17
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ciprofloxacin Hydrochloride 3 mg/mL 309309 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
28

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Cytochrome P450 1A2 Inhibitors [MoA] MoA All 31 members
Fluoroquinolone Antibacterial [EPC] EPC All 20 members
Fluoroquinolones [CS] CS All 20 members
Quinolone Antimicrobial [EPC] EPC All 16 members
Quinolones [CS] CS All 16 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
019992
Application type
NDA · New Drug Application
Approval date
December 31, 1990
Sponsor
SANDOZ
Products on application
1
Submissions recorded
20
Products approved under application 019992.
Product Trade name Form Strength Ingredient Status TE Flags
019992-001 CILOXAN SOLUTION/DROPS CIPROFLOXACIN HYDROCHLORIDE Prescription AT RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 019992.
Type No. Action Status Date Review
Supplement 26 Labeling Approved March 21, 2017 Standard
Supplement 20 Labeling Approved February 7, 2006 Standard
Supplement 19 Labeling Approved August 20, 2004 Standard
Supplement 16 Manufacturing (CMC) Approved March 13, 2002 Standard
Supplement 15 Manufacturing (CMC) Approved September 14, 2001 Standard
Supplement 14 Manufacturing (CMC) Approved March 16, 2001 Standard
Supplement 13 Manufacturing (CMC) Approved February 18, 2000 Standard
Supplement 8 Manufacturing (CMC) Approved November 9, 1999 Standard
Supplement 12 Manufacturing (CMC) Approved August 17, 1999 Standard
Supplement 10 Manufacturing (CMC) Approved March 11, 1999 Standard
Supplement 11 Manufacturing (CMC) Approved February 5, 1999 Standard
Supplement 9 Manufacturing (CMC) Approved October 14, 1998 Standard
Supplement 7 Manufacturing (CMC) Approved January 15, 1998 Standard
Supplement 6 Manufacturing (CMC) Approved November 1, 1995 Standard
Supplement 5 Manufacturing (CMC) Approved November 1, 1995 Standard
Supplement 4 Efficacy Approved October 27, 1994 Standard
Supplement 2 Manufacturing (CMC) Approved October 27, 1993 Standard
Supplement 3 Manufacturing (CMC) Approved January 22, 1993 Standard
Supplement 1 Manufacturing (CMC) Approved February 12, 1992 Standard
Original application 1 Type 3 - New Dosage Form Approved December 31, 1990 Standard

Review documents

  • 0 · Supplement · March 24, 2017
  • 0 · Supplement · March 22, 2017
  • 0 · Supplement · February 8, 2006
  • 0 · Supplement · February 8, 2006
  • 0 · Supplement · August 25, 2004
  • 0 · Supplement · August 25, 2004
  • 0 · Original application · January 1, 1900

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260327). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260327 HUMAN PRESCRIPTION DRUG · 20251105 HUMAN PRESCRIPTION DRUG · 20250203

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred. Bacterial Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

WARNINGS: NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. Remove contact lenses before using.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (see PRECAUTIONS ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

openFDA Drug Labeling

Drug Interactions: Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Description

openFDA Drug Labeling

DESCRIPTION Ciprofloxacin Hydrochloride Ophthalmic Solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C 17 H 18 FN 3 O 3 •HCl•H 2 O and its chemical structure is as follows: Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. Each mL of Ciprofloxacin Hydrochloride Ophthalmic Solution contains: Active: ciprofloxacin HCl 3.5 mg equivalent to 3 mg base. Preservative: benzalkonium chloride 0.006%. Inactive: sodium acetate, acetic acid, mannitol 4.6%, edetate disodium 0.05%, hydrochloric acid and/or sodium hydroxide (to adjust pH) and purified water. The pH is approximately 4.5 and the osmolality is approximately 300 mOsm. chemical

OVERDOSAGE A topical overdose of Ciprofloxacin Hydrochloride Ophthalmic Solution may be flushed from the eye(s) with warm tap water.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: As a sterile ophthalmic solution in Alcon’s DROP-TAINER ® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC: 70518-1170-00 NDC: 70518-1170-01 PACKAGING: 1 in 1 CARTON, 5 mL in 1 BOTTLE PLASTIC PACKAGING: 1 in 1 CARTON, 2.5 mL in 1 BOTTLE PLASTIC Storage: Store at 2°C to 25°C (36°F - 77°F). Protect from light. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

Adverse event reports

Source: openFDA FAERS
96,908
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CIPROFLOXACIN HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II June 15, 2022 Mckesson Medical-Surgical Inc. Corporate Office cGMP deviations: Temperature abuse Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0882-0 50090-0882 A-S Medication Solutions 1 BOTTLE, PLASTIC in 1 CARTON (50090-0882-0) / 5 mL in 1 BOTTLE, PLASTIC November 28, 2014
50090-1754-0 50090-1754 A-S Medication Solutions 1 BOTTLE, PLASTIC in 1 CARTON (50090-1754-0) / 2.5 mL in 1 BOTTLE, PLASTIC March 20, 2015
76420-942-03 76420-942 Asclemed USA, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-03) / 2.5 mL in 1 BOTTLE, PLASTIC March 29, 2025
76420-942-05 76420-942 Asclemed USA, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-05) / 5 mL in 1 BOTTLE, PLASTIC March 29, 2025
76420-942-10 76420-942 Asclemed USA, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-10) / 10 mL in 1 BOTTLE, PLASTIC March 29, 2025
68071-3351-3 68071-3351 NuCare Pharmaceuticals,Inc. 10 mL in 1 BOX (68071-3351-3) July 20, 2017
68071-4139-5 68071-4139 NuCare Pharmaceuticals,Inc. 5 mL in 1 BOX (68071-4139-5) November 1, 2017
68071-4235-3 68071-4235 NuCare Pharmaceuticals,Inc. 2.5 mL in 1 BOX (68071-4235-3) January 17, 2018
68788-8198-5 68788-8198 Preferred Pharmaceuticals Inc. 1 BOTTLE, PLASTIC in 1 CARTON (68788-8198-5) / 5 mL in 1 BOTTLE, PLASTIC May 23, 2022
63187-985-05 63187-985 Proficient Rx LP 1 BOTTLE, PLASTIC in 1 CARTON (63187-985-05) / 5 mL in 1 BOTTLE, PLASTIC March 1, 2018
63187-985-10 63187-985 Proficient Rx LP 1 BOTTLE, PLASTIC in 1 CARTON (63187-985-10) / 10 mL in 1 BOTTLE, PLASTIC December 1, 2018
70518-1170-0 70518-1170 REMEDYREPACK INC. 1 BOTTLE, PLASTIC in 1 CARTON (70518-1170-0) / 5 mL in 1 BOTTLE, PLASTIC May 15, 2018
67296-0142-1 67296-0142 Redpharm Drug 1 BOTTLE, PLASTIC in 1 CARTON (67296-0142-1) / 5 mL in 1 BOTTLE, PLASTIC May 7, 2004
67296-0142-2 67296-0142 Redpharm Drug 2 BOTTLE, PLASTIC in 1 CARTON (67296-0142-2) / 5 mL in 1 BOTTLE, PLASTIC May 7, 2004
61314-656-05 61314-656 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-05) / 5 mL in 1 BOTTLE, PLASTIC May 7, 2004
61314-656-10 61314-656 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-10) / 10 mL in 1 BOTTLE, PLASTIC May 7, 2004
61314-656-25 61314-656 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-25) / 2.5 mL in 1 BOTTLE, PLASTIC May 7, 2004
50090-0882 50090-0882 A-S Medication Solutions — May 7, 2004
50090-1754 50090-1754 A-S Medication Solutions — May 7, 2004
76420-942 76420-942 Asclemed USA, Inc. — May 7, 2004
68071-3351 68071-3351 NuCare Pharmaceuticals,Inc. — May 7, 2004
68071-4139 68071-4139 NuCare Pharmaceuticals,Inc. — May 7, 2004
68071-4235 68071-4235 NuCare Pharmaceuticals,Inc. — May 7, 2004
68788-8198 68788-8198 Preferred Pharmaceuticals Inc. — May 23, 2022
63187-985 63187-985 Proficient Rx LP — May 7, 2004
70518-1170 70518-1170 REMEDYREPACK INC. — May 15, 2018
67296-0142 67296-0142 Redpharm Drug — May 7, 2004
61314-656 61314-656 Sandoz Inc — May 7, 2004

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.